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Abstract
Purpose The main aim of this paper is to present baseline demographic and clinical characteristics and HRQOL in the two 
groups of the Patient Concerns Inventory (PCI) trial. The baseline PCI data will also be described.
Methods This is a pragmatic cluster preference randomised control trial with 15 consultant clusters from two sites either 
‘using’ (n = 8) or ‘not using’ (n = 7) the PCI at a clinic for all of their trial patients. The PCI is a 56-item prompt list that helps 
patients raise concerns that otherwise might be missed. Eligibility was head and neck cancer patients treated with curative 
intent (all sites, stage of disease, treatments).
Results From 511 patients first identified as eligible when screening for the multi-disciplinary tumour board meetings, 288 
attended a first routine outpatient baseline study clinic after completion of their treatment, median (IQR) of 103 (71–162) 
days. At baseline, the two trial groups were similar in demographic and clinical characteristics as well as in HRQOL measures 
apart from differences in tumour location, tumour staging and mode of treatment. These exceptions were cluster (consult-
ant) related to Maxillofacial and ENT consultants seeing different types of cases. Consultation times were similar, with PCI 
group times taking about 1 min longer on average (95% CL for the difference between means was from − 0.7 to + 2.2 min).
Conclusion Using the PCI in routine post-treatment head and neck cancer clinics do not elongate consultations. Recruitment 
has finished but 12-month follow-up is still ongoing.
Keywords Head and neck cancer · Intervention · Prompt list · Health-related quality of life · Randomised trial · Patient 
concerns inventory · Cluster preference
Introduction
Following head and neck cancer (HNC) patients can expe-
rience substantial physical, emotional, and social dysfunc-
tion as post-treatment consequences effects many aspects 
with a detrimental impact on health-related quality of life 
(HRQOL) [1, 2]. These in turn can lead to a significant 
burden of unmet supportive care needs [3]. There is evi-
dence that given the opportunity patients value the chance to 
discuss their concerns [4]. There are various tools available 
to assist the clinician in the identification of potential unmet 
needs in the HNC setting, of which the Patient Concerns 
Inventory (PCI) is one. In a systematic review, Shunmu-
gasundaram et al. recommended the PCI, particularly when 
considering the importance of content validity over quanti-
tative psychometric properties [5]. The PCI is a condition-
specific item prompt list [6] and is based on the literature 
around the use of questionnaire prompt lists in consultations 
[7]. It consists of 56 items, which patients select from before 
their appointment, to help guide the outpatient consultation, 
which covers a range of symptoms and potential problems 
individuals may confront after treatment. The PCI helps to 
focus the consultation, to aid doctor-patient communication, 
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and to signpost patients to other professionals for advice and 
support [8]. It is a tool that can be integrated into routine 
clinical practice [9].
Although pilot work has confirmed that most patients 
wish to continue to use the PCI in their consultations [10], 
and that its inclusion alters the items discussed with clini-
cians and potentially improves HRQOL [11, 12], there is a 
lack of evidence from a randomised trial of patient benefit, 
which has prompted this novel trial [13]. By conducting a 
pragmatic, cluster-based, multi-centre randomised controlled 
trial (C-RCT) involving several consultants, it will be pos-
sible to evaluate with rigor, whether the repeated inclusion 
of the PCI in routine post-treatment consultations does make 
a significant and clinically meaningful difference in patient-
reported HRQOL and distress.
The main aim of this paper is to present baseline demo-
graphic and clinical characteristics and HRQOL in the two 
groups of the Patient Concerns Inventory (PCI) trial. Also, 
to describe the baseline PCI data. The baseline data provides 
the opportunity to describe HRQOL and patient concerns 
relatively early on in the post-treatment trajectory. Having 
a greater understanding of early post-treatment issues and 
challenges could help shape interventions at this critical time 
of adaptation to the cancer diagnosis and the consequences 
of treatment.
Material and methods
The study methods have been described previously [13]. 
Briefly, this is a pragmatic cluster-controlled trial, with 
consultants (clusters) randomised to ‘using’ or ‘not using’ 
an intervention incorporating the PCI prompt list at all their 
trial clinics. Individual patient randomisation was ruled out 
because of the likely sensitization of consultants to using the 
PCI. Such sensitization could lead to certain strategies being 
carried over to when control group patients were being seen, 
and consequently a possible dilution of any intervention 
effect. It is also a consultant preference trial, by which those 
with preferences were given their preferred group and those 
with no preference were randomised. This was to limit the 
chance of PCI-sceptic consultants dominating the PCI group 
and PCI-enthusiastic consultants the non-PCI group. The 
allocation process was overseen by the trial medical statisti-
cian, before any patient recruitment occurred. Two centres 
participated. In Leeds, three of six consultants preferred to 
be in the PCI group, while the three others had no preference 
and were placed in the control group. In Liverpool, three of 
eight consultants preferred to be controls and the other five 
had no preference: one was randomised to the control group 
and the other four were placed in the PCI intervention group. 
One newly appointed consultant at Liverpool joined the trial 
soon after it started and was randomised to the PCI group.
Sample size calculations required 312 patients from 
ten or more consultants to show (with 80% power, 5% 
level of significance) a halving in the percentage with less 
than the good overall quality of life at the final follow-up 
clinic, i.e. at 1-year on from the (baseline) first routine 
outpatient clinic after completion of treatment. With an 
expected 25% loss through attrition and non-consent, 416 
was the required number to be identified at Multidiscipli-
nary Team (MDT) Meetings. Eligible patients were given 
an information sheet about the trial and if willing they 
were asked to sign a consent form when they next attended 
hospital. Patients consented to their clinical data being 
used and to completing research questionnaires before 
each post-treatment consultation, some of which could be 
used in their consultation. Neither consultants nor patients 
were blind to the randomisation; this was a pragmatic 
trial. Eligible patients were treated curatively for primary 
HNC, and all sites, stages of disease and treatments were 
included. Patients with a second primary tumour were also 
accepted from January 2018. Patients treated palliatively 
and patients with a recurrence were excluded, as were 
patients with a history of cognitive impairment, psychoses 
or dementia. Eligible patients who later started palliative 
care discontinued their participation. Unit Clinical Tri-
als Nurses recruited patients and dedicated funded Unit 
researchers collected baseline clinical and demographic 
data using a baseline clinic questionnaire based on that 
of the Head and Neck 5000 project [14], or by extraction 
from baseline clinical records. Index of Multiple Depriva-
tion (IMD 2019) scores were derived from patient post-
codes using publicly available data [15] and these provide 
a relative measure of deprivation at a small area level 
across England. Trial Quality Assurance included initial 
training and immediate post-consultation feedback from 
PCI patients about how much use had been made of the 
PCI prompt list.
Pre-consultation questionnaires including the PCI prompt 
list were completed electronically (desktop, tablet, iPAD) 
apart from at one Liverpool hospital (non-PCI consult-
ant) which used paper because of technical issues. All PCI 
intervention group patients were then given a sheet of paper 
summarising their data which they took into their consulta-
tions (Fig. 1). This sheet listed (a) all the PCI items they 
had selected for discussion, (b) any University of Washing-
ton (UWQOL) questionnaire domains in which a signifi-
cant problem or dysfunction was indicated, (c) their overall 
UWQOL response and (d) their Distress Thermometer score. 
This summary sheet was the visible difference between 
the trial arms as far as the contact between consultant and 
patient was concerned. Control patients completed exactly 
the same pre-clinic information as intervention patients apart 
from the PCI prompt list, but crucially both they and their 
consultant did not see any summary sheet.
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Measures
The UW-QOL v4 questionnaire consists of 12 single-item 
domains, these having between 3 and 5 response options 
scaled evenly from 0 (worst) to 100 (best) according to 
response hierarchy [16]. UW-QOL domains are presented 
within two subscales, physical function and social-emotional 
function [17]. The physical function score is the mean of the 
appearance, swallowing, chewing, speech, taste and saliva 
domain scores, while the social-emotional function score is 
the mean of the pain, activity, recreation, shoulder, mood, 
and anxiety domain scores. Criteria derived from earlier 
work can be used to indicate the domains in which patients 
have a significant problem or dysfunction [18]. Question 
domains for intimacy and fears of recurrence were also 
developed using a similar system of possible responses as 
the UWQOL v4 [19, 20]. There is also a single item over-
all QOL question on the UWQOL v4 for which patients 
are asked to consider not only physical and mental health, 
but also other factors, such as family, friends, spirituality or 
personal leisure activities important to their enjoyment of 
life. The trial primary outcome measure is the percentage of 
patients with less than good overall QOL at the final 1-year 
clinic. As inference will target the individual patient level, 
the final analyses will include the adjustment for consult-
ant clustering as well as for baseline variables including the 
baseline value of the QOL measure. Secondary outcomes 
include the mean social-emotional subscale score of the 
UWQOL-v4 and a Distress Thermometer (DT) score of 4 or 
more [21]. These will be reported once the trial has finished. 
HRQOL data also included the EQ-5D-5L [22].
Statistical analysis
For cluster randomised trials the risk of chance imbalance is 
greater than for individual patient randomisation because of 
the relatively small number of clusters involved. It is there-
fore prudent to present relevant summary baseline infor-
mation for both clusters (consultants) and patients. Fishers 
Exact (for categorical variables) and the Mann–Whitney test 
(for numerical variables) were used at the individual level to 
compare the case-mix of the two groups.
Results
Recruitment process and participation rate
Patients recruited to the trial and having baseline data were 
first discussed at MDT meetings between January 2017 
and December 2018, with baseline trial clinics between 
April 2017 and October 2019. MDT meetings identified 
511 potentially eligible patients (Fig. 2), with 288 attend-
ing baseline clinics a median (IQR) of 194 (125–249) days 
Fig. 1  Example of a summary 
sheet that PCI patients took into 
their consultation
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after diagnosis, and 103 (71–162) days after the end of 
treatment. The 223 patients not starting the trial included 
111 who could not possibly have started it because of what 
materialised in the time lag between MDT and the trial 
baseline clinic to make them ineligible; these comprised 48 
lost through death, tumour recurrence or palliation, 21 lost 
because it was more convenient for some patients to travel 
to a non-trial site, 22 because of delays in trying to agree an 
electronic system at one hospital and 20 for clinical reasons 
(in another trial, mental health, not HNC, 2nd Primary). 
Fig. 2  Patient flow diagram
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The other 112 patients lost to the trial comprised 71 due to 
consent being refused, five who withdrew consent, nine by 
missed opportunity to recruit within a busy outpatient clinic 
environment, six when there was no translator available, four 
with exclusions outside the trial protocol (clinical opinion, 
patient age) and 17 lost to follow-up/unknown status. All 15 
eligible consultants from the two locations took part in the 
trial, with a median (range) of 16 (5–48) patients attending 
baseline clinics.
Randomisation baseline comparisons
At the cluster (consultant) level there was a similarity 
between trial groups in the number of patients per con-
sultant, median consultation times, mean patient ages, and 
experience (Table 1). There was also a similarity in regard 
to the primary outcome variable as measured at baseline, 
i.e. the percentage with less than the good overall quality 
of life, as well as for key secondary measures, namely the 
mean social-emotional subscale score of the UWQOL and 
the percentage of patients reporting a distress thermome-
ter score of four or more. However, there were differences 
between trial groups in the type of patient (tumour location 
and staging) seen by consultants and in treatments admin-
istered. PCI group consultants had fewer patients with oral 
cavity tumours, more with advanced tumour staging, and 
more receiving radiotherapy and chemotherapy. These 
differences in consultant case-mix transferred through to 
patient-level (Table 2), though less markedly reflecting the 
way the variation in patients per consultant has played out 
Table 1  Baseline comparisons at the cluster (consultant) level
The results bold are those of the three consultants with fewer than ten study patients. These results are liable to greater fluctuation
PCI group Control group
Consultant level
No of consultants (patients) 8 (140) 7 (148)
No of patients in trial Median: 16
Range: 9, 15, 15, 16, 16, 18, 23, 28
Median: 17
Range: 5, 6, 13, 17, 26, 33, 48
Year started as a consultant Median: 2009
Range: 97, 01, 06, 07, 10, 14, 17, 17
Median: 2009
Range: 03, 05, 09, 09, 13, 15, 15
Specialty ENT or MFU 5 ENT, 3 MFU 2 ENT, 5 MFU
Consultation times (minutes) Median Median: 11
9, 10, 10, 11, 11, 11, 13, 15
Median: 11
Range: 7, 8, 10, 11, 11, 12, 12
% of patients having Surgery Median: 30
Range: 0, 13, 25, 27, 32, 52, 60, 72
Median: 58
Range: 17, 40, 41, 58, 58, 62, 67
RT or RT/CT Median: 38
Range: 0, 0, 7, 38, 38, 43, 47, 67
Median: 6
Range: 0, 0, 0, 6, 8, 31, 40
Surgery & (RT or RT/CT) Median: 33
Range: 25, 27, 28, 33, 33, 38, 48, 50
Median: 38
Range: 20, 33, 35, 38, 42, 52, 53
% of patients with Advanced 3–4 staging Median: 69
Range: 33, 39, 47, 68, 69, 73, 81, 89
Median: 50
Range: 31, 31, 39, 50, 60, 65, 79
% of patients with tumour location Oral cavity Median: 15
Range: 0, 0, 4, 7, 22, 80, 89, 100
Median: 77
Range: 0, 2, 77, 77, 82, 85, 100
Oropharynx Median: 37
Range: 0, 6, 7, 33, 40, 46, 56, 56
Median: 15
Range: 0, 8, 9, 15, 18, 60, 73
Larynx Median: 22
Range: 0, 0, 7, 11, 32, 38, 40, 44
Median: 0
Range: 0, 0, 0, 0, 0, 19, 40
Other Median: 7
Range: 0, 0, 6, 6, 7, 13, 18, 33
Median: 6
Range: 0, 0, 0, 6, 6, 8, 15
Patient age at baseline Median Median: 63
Range: 58, 61, 61, 62, 63, 63, 64, 65
Median: 61
Range: 57, 57, 59, 61, 62, 63, 68
Patient gender % Female Median: 32
Range: 13, 13, 21, 31, 33, 44, 47, 70
Median:31
Range: 0, 13, 24, 31, 39, 45, 50
UWQOL Overall Quality of life % Less than good Median: 34
Range: 22, 22, 25, 32, 35, 38, 40, 40
Median: 27
Range: 0, 23, 24, 27, 33, 38, 42
UWQOL social-emotional subscale Median Median: 78
Range: 65, 70, 76, 78, 78, 83, 83, 85
Median: 78
Range: 63, 67, 69, 78, 78, 83, 85
Distress thermometer (DT) % ≥ 4 Median: 56
Range: 30, 32, 33, 56, 56, 60, 63, 67
Median: 54
Range: 29, 31, 31, 54, 55, 60, 67
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Table 2  Baseline case-mix comparisons at the patient level
PCI group N = 140 Control group
N = 148
P value
Hospital Aintree 59% (82) 65% (96) 0.28
Leeds 41% (58) 35% (52)
Days from diagnosis to baseline clinic Median (IQR) 189 (120–255) 195 (125–244) 0.68
Days from end of treatment to baseline clinic Median (IQR) 108 (70–165) 102 (75–160) 0.90
Duration of consultation (minutes) Mean, Median (IQR) 11.9, 11 (8–15), n = 137 11.1, 10 (7–13), n = 147 0.09
Gender Female 35% (49) 28% (41) 0.20
Age at baseline Median (IQR) 63 (57–69) 60 (53–68) 0.12
Ethnicity A1 (White British) 99% (138) 95% (141) 0.17
Tumour site Oral cavity 39% (55) 53% (79) 0.002
Oropharynx 30% (42) 33% (49)
Larynx 21% (30) 7% (11)
Other 9% (13) 6% (9)
Clinical T stage 3–4 21% (30) 24% (36) 0.58
Clinical N stage Positive 54% (75) 44% (65) 0.13
Overall stage 0/I 26% (36) 32% (48) 0.47
II 14% (20) 14% (20)
III 20% (28) 14% (21)
IV 40% (56) 40% (59)
Primary treatment Surgery only 38% (53) 43% (63) 0.02
RT only 9% (13) 2% (3)
RT&CT only 18% (25) 11% (17)
Surgery and RT 27% (38) 36% (54)
Surgery and RT and CT 8% (11) 7% (11)
Free-flap transfer YES 25% (25/102) 33% (42/128) 0.19
WHO comorbidity 0 63% (88) 61% (91) 0.28
1 20% (28) 26% (39)
2–4 17% (24) 12% (18)
ACE27 comorbidity None 51% (71) 45% (66) 0.52
Mild 29% (41) 36% (54)
Moderate 18% (25) 16% (23)
Severe 2% (3) 3% (5)
Living situation Alone in house/flat 21% (29) 25% (36/146) 0.48
Working Yes 36% (48/134) 27% (40/146) 0.16
Financial benefits Yes 39% (49/127) 42% (58/138) 0.62
Smoking habit Current 12% (16/135) 14% (21/145) 0.77
Former 60% (81/135) 57% (82/145)
Never 28% (38/135) 29% (42/145)
Alcohol habit Current 74% (100/135) 65% (94/145) 0.25
Former 22% (30/135) 30% (43/145)
Never 4% (5/135) 6% (8/145)
IMD 2019 quintile 1 = least deprived 11% (16) 12% (18) 0.83
2 21% (29) 18% (26)
3 16% (22) 18% (27)
4 12% (17) 16% (23)
5 = most deprived 40% (56) 36% (54)
European Archives of Oto-Rhino-Laryngology 
1 3
in the aggregation of data. Apart from these differences the 
two trial groups were similar in demographic and clinical 
characteristics. Of particular note is that consultation times 
were very similar, with PCI group times taking about 1 min 
longer on average (95% confidence interval for the difference 
between means was from 0.7 of a minute less to 2.2 min 
longer). There was also a similarity in regard to the primary 
outcome variable as measured at baseline, as well as for the 
key secondary measures, and also across a wide range of 
baseline QOL measures (Table 3).
Baseline study population characteristics
Median (IQR) age at baseline clinic of the 288 patients was 
62 (55–69) years and 69% (198) were male. For 47% (134) 
the tumour was located in the oral cavity, 32% (91) oro-
pharynx, 14% (41) larynx and 8% (22) in other places. All 
but six tumours were squamous cell (SCC). Clinical staging 
was early (0–2) for 43% (124) and advanced (3–4) for 57% 
(164). Treatment for 40% (116) comprised surgery alone 
while 6% (16) received radiotherapy without surgery, 15% 
(42) radiotherapy and chemotherapy without surgery, 32% 
(92) surgery with adjuvant radiotherapy and 8% (22) sur-
gery with adjuvant radiotherapy and chemotherapy. Free-
flap transfer occurred for 29% (67/230) of operations, and 
specifically for 46% (60/130) of tumours in the oral cav-
ity, 8% (5/61) oropharynx, 4% (1/23) larynx, and 6% (1/16) 
other locations. WHO comorbidities were at level 1 for 23% 
(67), level 2 for 13% (36), levels 3–4 for 2% (6). ACE 27 
comorbidities were mild for 33% (95), moderate for 17% 
(48), and severe for 3% (8). Most patients had smoked with 
13% (37/280) currently smoking at the time of the base-
line questionnaire, 58% (163/280) being former smokers 
and 29% (80/280) having never smoked. Two-thirds (69%, 
194/280) continued to drink alcohol, 26% (73/280) no longer 
did so and 5% (13/280) had never drank alcohol. One quarter 
(23%, 65/286), lived alone in a house or flat, 31% (88/280) 
were still working in paid employment, and 40% (107/265) 
were in receipt of financial benefits. Some 38% (110/288) of 
patients lived in an area that is ranked nationally (England) 
within the most deprived 20% of areas, according to overall 
deprivation scores (IMD 2019).
Overall QOL was outstanding for 6% (18), very good for 
30% (87), good for 33% (94), fair for 22% (63), poor for 6% 
(17) and very poor for 3% (9); i.e. 31% (89) had overall QOL 
that was less than good and 69% (199) had overall QOL that 
was good or better. Also, 45% (129) stated Distress Ther-
mometer values of ≥ 4 and the median (IQR) UWQOL emo-
tional subscale score was 75 (59–88). Dysfunction in regard 
to UWQOL items were notably higher in regard to salivation 
(34%, 99), pain (29%, 83), fears of recurrence (26%, 75), and 
taste (20%, 57).
The mean number of items selected by 140 PCI patients 
for discussion in their consultation was 6.60, median (IQR) 
5 (2–9), range 0–28 with 15 or more items selected by 9% 
(13) (Table 4). Nearly half (48%) of patients selected ‘dry 
mouth’ to discuss and other items selected by more than 20% 
were ‘fear of cancer coming back’ (34%), ‘dental health/
teeth’ (34%), ‘chewing/eating’ (33%), ‘salivation’ (33%), 
‘fatigue/tiredness’ (29%), ‘swallowing’ (28%), ‘taste’ 27%, 
‘sore mouth’ (24%), ‘mucus’ (24%), ‘shoulder’ (22%), ‘pain 
in the head and neck’ (21%) and ‘cancer treatment’ (20%), 
(Table 4, Fig. 3). Almost all the immediate post-consultation 
feedback was positive in that the PCI had been used ‘a great 
deal’ or ‘somewhat’ in the consultation. The PCI results 
were broadly similar for the two sites involved in the trial. 
Discussion
The main focus of this paper is to assess the baseline bal-
ance in this trial. Ivers et al. comment that many cluster 
randomised trials (C-RCTs) have too few clusters to reason-
ably expect cluster level balance [23]. They cite a review 
of C-RCTs with a median of 21 clusters per trial with 25% 
having fewer than 12 clusters. Our trial recruited 15 consult-
ant clusters and we have presented data at both cluster and 
patient levels. The two trial groups were broadly similar at 
the patient level in demographic and clinical characteristics 
and over a wide range of QOL measures, apart from differ-
ences in regard to tumour location, tumour staging, and the 
mode of treatment. These exceptions are cluster (consultant) 
related to Maxillofacial and ENT consultants seeing differ-
ent types of cases. Baseline imbalances are unimportant if 
the variable concerned is unrelated to the outcome, while 
strong predictors of outcome are important even if statisti-
cally non-significant [24]. It is important to identify strong 
baseline predictors and to adjust for these in the final analy-
ses [25]. Our trial protocol named age, gender, treatment, 
overall clinical stage, and tumour site as case-mix variables 
that will be adjusted for. As the outcome data is awaited the 
strongest predictors are yet to be identified. We will also 
adjust for the baseline value of the QOL outcome so as to 
adjust for any imbalances between PCI and control groups.
A 1-year unfunded extension to the trial was necessary 
for various reasons. Firstly, the MDT identified potential 
patients in a wide catch-all net so as not to miss eligible 
patients but in so doing this process flagged patients who on 
closer scrutiny could never have been included had the con-
senting process taken place at the first post-treatment routine 
clinical outpatient review. This applied to 50% of those lost 
to the trial between MDT and trial baseline clinic. Secondly 
there were delays in setting up the IT capacity (iPAD) at a 
spoke unit and after several months trying to resolve this 
issue it was decided to allow paper completion because this 
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Table 3  Baseline clinic QOL comparisons at the patient level
PCI group Control group
N = 140 N = 148
Main outcome measures
 UWQOL Overall Quality of life Less than good 32% (45) 30% (44)
 UWQOL social-emotional subscale Mean, Median (IQR) 75, 78 (64–87) 70, 72 (55–88)
 Distress thermometer (DT) Score ≥ 4 47% (66) 43% (63)
Other measures
 UWQOL Overall Quality of life Outstanding 8% (11) 5% (7)
Very good 26% (36) 34% (51)
Good 34% (48) 31% (46)
Fair 24% (34) 20% (29)
Poor 4% (5) 8% (12)
Very Poor 4% (6) 2% (3)
UWQOL physical function subscale Mean, Median (IQR) 69, 69 (57–86) 67, 68 (53–86)
UWQOL items
 Social-emotional subscale
  Pain Best possible response 38% (53) 37% (55)
Dysfunction 28% (39) 30% (44)
  Activity Best possible response 33% (46) 27% (40)
Dysfunction 10% (14) 14% (20)
  Recreation Best possible response 44% (61) 32% (48)
Dysfunction 6% (8) 10% (15)
  Shoulder Best possible response 61% (85) 51% (75)
Dysfunction 10% (14) 15% (22)
  Mood Best possible response 34% (48) 33% (49)
Dysfunction 12% (17) 19% (28)
  Anxiety Best possible response 34% (47) 38% (56)
Dysfunction 17% (24) 17% (25)
 Physical function subscale
  Appearance Best possible response 31% (43) 22% (32)
Dysfunction 8% (11) 11% (17)
  Swallowing Best possible response 36% (50) 36% (54)
Dysfunction 12% (17) 17% (25)
  Chewing Best possible response 41% (57) 41% (60)
Dysfunction 14% (19) 13% (19)
  Speech Best possible response 46% (64) 40% (59)
Dysfunction 7% (10) 9% (13)
  Taste Best possible response 29% (41) 33% (49)
Dysfunction 19% (27) 20% (30)
  Saliva Best possible response 29% (41) 26% (39)
Dysfunction 37% (52) 32% (47)
 Other items
  Intimacy Best possible response 79% (110) 69% (102)
Dysfunction 4% (6) 6% (9)
  Fear of recurrence Best possible response 14% (19) 16% (24)
Dysfunction 25% (35) 27% (40)
EQ-5D
 Mobility Moderate/severe/unable 18% (25) 27% (40)
 Self-care Moderate/severe/unable 11% (16) 11% (16)
 Usual activities Moderate/severe/unable 21% (29) 28% (42)
 Pain Moderate/severe/extreme 31% (44) 30% (44)
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involved only one non-PCI consultant. Vigilance of the clini-
cal trials team at this site enabled robust data completion. IT 
difficulties do raise a wider issue around the future rollout 
of the PCI approach in HNC consultations across the NHS 
and currently a cloud-based platform is being explored. A 
third reason for extending the trial period was a long time 
lag to the baseline clinic than originally expected. The first 
baseline surgeon consultant review was at around 6 months 
following diagnosis, with a trial follow-up period of another 
year. Even with this trial extension to allow more patients to 
be recruited, the final outcomes will be analysed on fewer 
numbers than planned, probably on around two-thirds of the 
intended number. In hindsight an extra trial hospital would 
have been useful to the trial but we have to be pragmatic 
and in the final analyses accept that “size and power are 
irrelevant once the experiment has actually been carried out. 
At this point the trial is analysed using confidence intervals 
to show the plausible values for the treatment effects” [26].
The choice of a cluster design is a strength of the study 
because randomisation of consultants avoided contamina-
tion and possible dilution of results by consultants being 
sensitized with the PCI process. An additional robustness 
Table 3  (continued)
PCI group Control group
N = 140 N = 148
 Anxiety/depression Moderate/severe/extreme 11% (15) 22% (33)
 EQ-5D-5L TTO crosswalk values Mean, Median (IQR) 0.76, 0.77 (0.68–0.88) 0.70, 0.74 (0.58–0.88)
 Visual analogue scale (VAS) Mean, Median (IQR) 73, 75 (60–87) 71, 76 (59–85)
Table 4  Patient PCI data at the post-treatment baseline clinic
Aintree Leeds Combined
N = 82 N = 58 i = 140
No of PCI selected: overall Mean, Median (IQR) 6.91, 5 (2–10) 6.16, 5 (3–8) 6.60, 5 (2–9)
PCI items selected by domain
 No of PCI selected: Physical function Mean, Median (IQR) 5.28, 4 (2–8) 4.76, 5 (2–7) 5.06, 4 (2–7)
 No of PCI selected: cancer treatment Mean, Median (IQR) 0.35, 0 (0–1) 0.31, 0 (0–1) 0.34, 0 (0–1)
 No of PCI selected: social Mean, Median (IQR) 0.39, 0 (0–1) 0.16, 0 (0–0) 0.29, 0 (0–0)
 No of PCI selected: psychological Mean, Median (IQR) 0.89, 1 (0–1) 0.93, 1 (0–1) 0.91, 1 (0–1)
PCI items selected by at least 20% of patients Dry mouth 48% (39) 50% (29) 49% (68)
Fear of cancer coming back 34% (28) 34% (20) 34% (48)
Dental health/Teeth 30% (25) 40% (23) 34% (48)
Chewing/eating 34% (28) 31% (18) 33% (46)
Salivation 33% (27) 33% (19) 33% (46)
Fatigue/tiredness 27% (22) 31% (18) 29% (40)
Swallowing 32% (26) 22% (13) 28% (39)
Taste 28% (23) 26% (15) 27% (38)
Sore mouth 30% (25) 14% (8) 24% (33)
Mucus 21% (17) 28% (16) 24% (33)
Shoulder 22% (18) 22% (13) 22% (31)
Pain in the head and neck 18% (15) 26% (15) 21% (30)
Cancer treatment 20% (16) 21% (12) 20% (28)
No. of Health professionals selected Mean, Median (IQR) 1.13, 1 (0–2) 0.48, 0 (0–1) 0.86, 0 (0–1)
Post consultation feedback on the PCI
 Did the doctor make reference to the PCI prompt 
list during the consultation?
Not at all – – –
A little – 3 3
Somewhat 1 12 13
A great deal 80 37 117
unknown 1 6 7
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to the trial is the relatively small proportion of refusals and 
withdrawals, though this was anticipated given the very high 
participation levels for using the PCI in routine non-trial set-
tings [4, 9, 10]. The number missed for logistical reasons was 
also small. Good patient and consultant recruitment allow 
confidence in respect of representativeness and acceptance 
of the PCI approach into clinical practice. Another strength 
of the trial was the electronic data capture which has virtu-
ally eliminated missing data in the outpatient clinic setting 
apart from the trial baseline questionnaires which patients 
could complete as they wished and from post-consultation 
feedback information of PCI patients.
The baseline assessment reflects survivors at a median of 
6 months after diagnosis and 3 months after the end of treat-
ment and their clinical characteristics are typical of a HNC 
patient population. HRQOL data highlights the dysfunction 
relating to salivation/dry mouth both in the UWQOL and as 
the most commonly raised issue on the PCI. There was also 
notable dysfunction in regard to pain and in fearing their 
cancer would return, and these issues were also commonly 
raised on the PCI. Whereas just over two-thirds of patients 
regarded their overall QOL as being good or better, distress 
levels were relatively high with nearly half having Distress 
Thermometer scores of four or more.
Consultation times were similar between the two groups 
indicating that the use of the PCI did not appear to have 
impacted the timetabling of clinic sessions. There is evi-
dence around the benefit of questionnaire prompt lists [7]
and how its use re-directs the focus of the consultation 
time onto those most pertinent issues for each patient [27]. 
Furthermore, from the issues raised on the PCI, this allows 
the HN team to apportion the necessary type and level 
of healthcare and supportive interventions, hence a more 
efficient use of time and personalized approach to rou-
tine follow-up care [27]. The PCI consultations were only 
about 1 min longer than non-PCI consultations and this 
should have no bearing on delivery across the NHS. There 
is a good indication from the immediate post-consultation 
questionnaires that the PCI was being used ‘a great deal’ 
at baseline and this will also be tracked over later clinics. 
One of the main criticisms that has been raised about the 
PCI is the possibility that by allowing patients to raise a 
lot of issues this will extend the consultation time unduly. 
The median number of PCI items selected was five, with 
an inter-quartile range of 2–9, which implies that the vast 
majority of patients do have issues they want to talk about 
and sometimes they have a lot of issues with one in ten 
patients having selected 15 or more items at these trial 
baseline clinics. This raises the issue of prioritisation 
within the consultation and anecdotal feedback from PCI 
consultant training sessions would suggest that they are 
able to incorporate items identified seamlessly into their 
consultations. Previous taped consultations have revealed 
Fig. 3  Graphic–bar chart of PCI frequencies
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that the time spent on physical examination in the consul-
tation room, such as palpation of the neck, mouth exami-
nation and nasendoscopy takes just a few minutes [28]. 
As nasendoscopy takes longer this might account for the 
consultation time difference between ENT and MFU. In 
addition, it is possible to have relatively short consulta-
tions as these are set in the context of ongoing interven-
tion from a range of professionals such as Clinical Nurse 
Specialist, Speech and Language Therapist, Dietitian, and 
Physiotherapists. Patients use the opportunity outside of 
the consultation, either by phone, email, or face to face, 
to access their support if this is not explicitly triggered 
during the clinic visit.
As the trial is set within the context of NHS practice and 
involved 15 consultants across two centres, the findings 
should have generalisability. Recruiting clusters is often 
more difficult than recruiting individuals [23], however, in 
this trial all eligible consultants agreed to participate. The 
choice of a cluster design is a strength of the study because 
randomisation of consultants avoided contamination and 
possible dilution of results by consultants being sensitized 
with the PCI process. Patients were allocated to individual 
consultants through the cancer tracking referral process 
and there was no selection bias based on knowing which 
consultants were using PCI and which were not. This has 
been a source of contamination in other trials [29]. Anec-
dotally, there was very little discussion observed between 
trial patients by the trial staff in the waiting room prior to 
consultations, which minimises any possible dilution of 
any effects of the intervention.
Conclusion
The PCI trial is well balanced at baseline. Trial follow-up 
will continue until September 2020.
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